These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 12244484

  • 1. Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH.
    Alban S, Welzel D, Hemker HC.
    Semin Thromb Hemost; 2002 Aug; 28(4):369-78. PubMed ID: 12244484
    [Abstract] [Full Text] [Related]

  • 2. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
    Alban S, Gastpar R.
    Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
    Bendetowicz AV, Béguin S, Caplain H, Hemker HC.
    Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
    [Abstract] [Full Text] [Related]

  • 4. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M, Weltermann A, Nieszpaur-Los M, Schneider B, Fassolt A, Lechner K, Eichler HG, Kyrle PA.
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S, Wolz M, Nieszpaur-Los M, Schneider B, Lechner K, Eichler HG, Kyrle PA.
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [Abstract] [Full Text] [Related]

  • 7. Suppression of intimal hyperplasia with low molecular weight heparin in a sheep model.
    Ao PY, Hawthorne WJ, Coombs R, Fletcher JP.
    Int Angiol; 1999 Jun; 18(2):131-9. PubMed ID: 10424369
    [Abstract] [Full Text] [Related]

  • 8. Comparative pharmacokinetics of LMWHs.
    Samama MM, Gerotziafas GT.
    Semin Thromb Hemost; 2000 Jun; 26 Suppl 1():31-8. PubMed ID: 11011804
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).
    Collignon F, Frydman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J, Thébault JJ.
    Thromb Haemost; 1995 Apr; 73(4):630-40. PubMed ID: 7495071
    [Abstract] [Full Text] [Related]

  • 10. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G, Heiden M, Köhler M.
    Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K, Harder S, Picard-Willems B, Warnke A, Donath F, Bianchini P, Parma B, Blume H.
    J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
    [Abstract] [Full Text] [Related]

  • 14. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L, Shen-Tu J, Liu J, Chen J, Wu L, Huang M.
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J, Raschke R.
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [Abstract] [Full Text] [Related]

  • 20. The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma--a study in human volunteers.
    Bendetowicz AV, Kai H, Knebel R, Caplain H, Hemker HC, Lindhout T, Béguin S.
    Thromb Haemost; 1994 Nov; 72(5):705-12. PubMed ID: 7900078
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.